

**Amendment Training SOP (PM-9) Audit  
Conducted Q4 FY 2021**

75 protocol amendments reviewed (41 major amendments\* / 34 minor amendments)

<p>Random selection of 75 out of 215 amendments approved between February,1 2021 – June 30, 2021. Training records were available for 38 (26 major/12 minor) amendments (51%).</p>	<ul style="list-style-type: none"> <li>• There was adequate training documentation for 17 (11major/6 minor) amendments (47%).</li> <li>• Training was conducted: <ul style="list-style-type: none"> <li>○ via email for 23 (17 major/6 minor) amendments (61%),</li> <li>○ in person for 3 (1 major /2 minor) amendments (8%),</li> <li>○ via email and in person for 8 (6 major /2 minor) amendments (21%).</li> </ul> </li> <li>• Training tool was used for 9 (7 major /2 minor) amendments (24%).</li> <li>• Training log was used for 18 (11 major /7 minor) amendments (47%).</li> </ul>
<p><b>Overall Findings</b> (major/minor)</p>	<ul style="list-style-type: none"> <li>• Amendment training records were not located for 37 (15 major /22 minor) amendments (49%).</li> <li>• Of the 38 (26 major /12 minor) amendments that had training records available for review: <ul style="list-style-type: none"> <li>○ Amendment training was conducted more than 5 business days after the amendment IRB approval for 6 (23%) major and 3 (25%) minor amendments.</li> <li>○ Amendment training documentation was non adequate for 11 (42%) major and 3 (25%) minor amendments.</li> </ul> </li> </ul>
<p><b>Detailed Findings</b> (major/minor)</p>	<ul style="list-style-type: none"> <li>• “Read Receipt” return emails were not available in regulatory files (2 major /1 minor).</li> <li>• Only training log was available in regulatory files without specifying the process used to communicate amendment changes (2 major /2 minor).</li> <li>• Training documentation did not specify who is responsible for action items and in what timeframe (10 major).</li> </ul>

- Major amendments include but not limited to changes to eligibility, study design, drug administration, dose, study procedures, study related risks, informed consent document and/or requirement for re-consent.